成纤维细胞生长因子-23在慢性肾脏病矿物质骨病中的诊断效用
Diagnostic utility of FGF-23 in mineral bone disorder during chronic kidney disease.
作者信息
Albanese Luisa, Caliendo Gemma, D'Elia Giovanna, Passariello Luana, Molinari Anna Maria, Napoli Claudio, Vietri Maria Teresa
机构信息
Unity of Clinical and Molecular Pathology, AOU, University of Campania "Luigi Vanvitelli", Naples - Italy.
Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples - Italy.
出版信息
J Circ Biomark. 2022 Jan 8;11:1-4. doi: 10.33393/jcb.2022.2328. eCollection 2022 Jan-Dec.
Our data confirm that intact fibroblast growth factor 23 (iFGF-23) concentration is increased in patients with chronic kidney disease (CKD) and that it increases with disease progression (stages I-V). Therefore, iFGF-23 could be considered an early biomarker in the course of chronic kidney disease-mineral bone disorder (CKD-MBD), which has several aspects that make it potentially useful in clinical practice. The availability of an automated method for iFGF-23 assay may represent an added value in the management of the patient with CKD-MBD already from the early stages of the disease, before the increase of the routinely used laboratory parameters, 1-84 parathyroid hormone (PTH) and 25-OH-vitamin D (25-OH-vitD), which occur in more advanced stages of the disease.
我们的数据证实，慢性肾脏病（CKD）患者体内完整的成纤维细胞生长因子23（iFGF-23）浓度升高，且其浓度随疾病进展（I-V期）而增加。因此，iFGF-23可被视为慢性肾脏病-矿物质和骨异常（CKD-MBD）病程中的一种早期生物标志物，它具有多个方面的特性，使其在临床实践中具有潜在的应用价值。iFGF-23检测的自动化方法的可用性，可能在CKD-MBD患者疾病管理的早期阶段，即在疾病更晚期才会出现的常规使用实验室参数，即1-84甲状旁腺激素（PTH）和25-羟基维生素D（25-OH-vitD）升高之前，就代表了一种附加价值。
Zotero 插件